Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Thank you for standing by. My name is Kris and I will be your ...

Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse ...

FYCOMPA continues to deliver steady prescription numbers and generated net revenues of $32.1 million in the third quarter. The brand experienced a 12% decrease in net revenues compared to Q3 2023 ...

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) recently filed a Form 8-K with the Securities and Exchange Commission, detailing its financial performance for the third quarter of 2024. The company ...

Revising full-year 2024 net product revenue guidance for FIRDAPSE to be between $300 million and $310 million; reaffirming FYCOMPA net product revenue guidance to be between $130 million and $135 ...

Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY IncreaseRecord Revenues Driven by Continued Organic Growth in its Rare ...

The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic ...

AGAMREE® Q3 2024 Net Product Revenues of $15.0 Million, Demonstrating Early U.S. Launch Success FYCOMPA® Q3 2024 Net Product Revenues of $32.1 Million Q3 2024 GAAP Net Income of $43.9 Million, $0.35 ...

Common side effects that may be seen with levetiracetam can include sleepiness and mood changes. Fycompa (perampanel) treats focal seizures with or without secondarily generalized seizures and primary ...